UC Davis offers new brachytherapy treatment for prostate cancer
Potentially safer, more effective
In the fight against prostate cancer, accuracy is key to effective treatment.
Especially when radiation therapy is used to kill tumor cells, a precisely delivered dose can improve cure rates — and lessen the chances for unwanted side effects.
For patients with prostate cancer at an early stage and that has not spread beyond the prostate, UC Davis Comprehensive Cancer Center's Department of Radiation Oncology now offers a new generation of brachytherapy, a type of treatment in which radioactive seeds are implanted in the prostate, slowly delivering radiation to the target over several months.
The new therapy option rounds out the cancer center’s full armamentarium to treat prostate cancer, the leading cancer in men. About one in six men over age 50 will be diagnosed with prostate cancer.
At UC Davis Comprehensive Cancer Center, where an estimated 250 patients seek care for prostate cancer each year, a multidisciplinary group of specialists works on the best options for each individual patient. For patients considered low-risk, these include watchful waiting, surgery, external beam radiation and brachytherapy.
'Doing normal work the next day'
UC Davis prostate cancer patient Michael Redman was one of the first to take advantage of the new brachytherapy approach. The Rio Linda 68-year-old said he preferred brachytherapy to traditional radiation, which he had been told would require daily visits for more than six weeks.
While typical radiation can require up to 40 visits, brachytherapy is a one-time procedure that lasts just two to three hours.
“It was very easy,” he said. “When it was over, I went home and followed the guidelines. It seems like a procedure that really didn’t have any side effects. I was doing normal work the next day.”
Redman also liked the fact that his brother, who had brachytherapy for his prostate cancer, was still disease-free after six years.
96 percent disease-free after five years
Valicenti, a renowned expert in radiation treatments for prostate cancer and other tumors, has shown the benefits of brachytherapy. In a study published last year in the journal Urology, Valicenti and colleagues demonstrated that 96 percent of low-risk prostate cancer patients who underwent brachytherapy remained disease-free after five years.
“These results, as well as those from many other experienced radiation oncologists, consistently demonstrate excellent tumor control and relatively acceptable side effects for prostate seed implants,” Valicenti said. “We are really pleased to be able to offer this to our prostate cancer patients.”